Dr Reddys Laboratories Ltd Q1 FY2025 Concall Summary

Key Takeaways

• Strong quarter, investment-heavy: Revenue grew 14% YoY and gross margin hit 60.4%, but SG&A jumped 28% YoY as the company front-loaded capability-building and freight costs spiked, pulling EBITDA margin down 357 bps YoY.
• US generics base business is the engine: The US$50-60M QoQ jump came overwhelmingly from volume-led base business growth across multiple products, not a single shortage or new launch, a pattern management says has held for six years.
• Portfolio reshaping accelerates: The Nicotinell acquisition, Nestlé JV go-live, Takeda licensing, and Alvotech denosumab deal all landed this quarter, signaling a deliberate push beyond plain-vanilla generics into consumer care, biosimilars and branded partnerships.
• Biologics pipeline is now a disclosed, multi-year story: Denosumab launch next year, abatacept filing end of CY25, Rituximab US approval hoped for this year, and a string of EM licensing deals expected through the decade.
• What to watch next quarter: Whether the US base business momentum holds without the tailwind of competitor exits, the pace of SG&A normalization toward the 27.5-28% guided band, and any update on the two USFDA Form 483s issued in May and June.

US Generics: The Base Business Bet

• Volume-led, not event-led: The QoQ revenue jump of US$50-60M was driven primarily by existing products gaining volume and market share, with three new launches contributing but not dominating. Management explicitly pushed back on the idea that a single product shortage or competitor exit explained the growth.
• Six-year track record: The company has grown the US base business (excluding lenalidomide) in single digits every year for six years, compensating for price erosion through volume and share gains. Management expects that pattern to continue.
• Lenalidomide steady: Volume is growing exactly per the contract; the agreement structure, not market share capture, dictates the trajectory.
• Price erosion denial: When an analyst characterized base business price erosion as "high single digit," management refused the number and said it had not been stated.
• Launch cadence on track: The ~20-plus products per year US launch guidance is unchanged.

Israeli: "We are leveraging the fact that, if you recall our previous discussions, we want to be, give or take, it's never that accurate, in the sweet spot, in which we are delivering enough for the shareholders but also investing in the future."

Portfolio Reshaping: Deals & New Platforms

• Nicotinell acquisition: Acquired the 2nd largest brand in the Nicotine Replacement Therapy category in markets outside the US. Transaction expected to close in early Q4 of CY24, with phased operational transition.
• Nestlé JV go-live: The nutraceuticals joint venture becomes operational on August 1st, with both Dr. Reddy's products (e.g., Celevida) and Nestlé's products in scope from day one. Over time, the intent is to bring additional Nestlé brands into the JV for India. No significant P&L impact at the start.
• Takeda licensing: Licensed Vonoprazan, a novel gastrointestinal drug, for commercialization in India.
• Novartis Russia partnership: Will distribute Novartis's anti-diabetes brands Galvus and Galvus Met in the Russian retail market.
• Alvotech denosumab collaboration: Exclusive US commercialization rights for the biosimilar candidate, plus rights in Europe and the UK. Launch is next year.
• Ingenus cyclophosphamide: Exclusive US rights to commercialize Cyclophosphamide Injection.
• Nerivio expansion: The drug-free migraine device is now available in five countries: India, Germany, Spain, UK and South Africa.

Israeli: "For the billion-dollar, we will need to buy more."

Biologics Pipeline: The Long Game

• Denosumab: Launch next year; Dr. Reddy's will commercialize it themselves in the US, not through a partner.
• Abatacept: Filing targeted for end of calendar 2025, with launch expected end of calendar 2026 assuming timely approval.
• Rituximab: Recently approved in Europe; US approval hoped for later this year. Unlike the Fresenius partnership for Rituximab, subsequent biologics will be commercialized by Dr. Reddy's directly in the US.
• Emerging Markets licensing: A significant number of biologics licensing deals for EM are expected through the end of the decade.
• Aurigene biologics facility: A 70,000 sq.ft. CDMO biologics facility was inaugurated in Genome Valley, Hyderabad, with investment of a few hundred crores. It is primarily for R&D activities for innovators and is backed by contracts that pay for the investment.
• Bachupally expansion: Current capacity is 15 KL, target is 50 KL; additional capex will continue for at least two more years to reach that level.

India & Emerging Markets

• India revenue: Grew 15% YoY, but the Sanofi vaccine portfolio in-licensing drove the bulk of it. Excluding Sanofi, the base business grew mid-single digits in Q1. Management expects double-digit India growth for the full year even without further acquisitions, with inorganic adding on top.
• Vaccine bridge strategy: The Sanofi portfolio was acquired as a "bridge" or anchor product to enable future additional products in the vaccines segment, and came with Sanofi's sales people.
• Russia resilience: Russia business grew 12% YoY in constant currency, driven by market share expansion and new products.
• Emerging Markets overall: Constant-currency growth of 9.8%, with market share gains and new products offsetting unfavorable forex.
• Europe generics: 4% YoY growth from base business volumes and new launches, partially offsetting price erosion.

Margins & Investment

• SG&A breakdown: The main driver is investment in capabilities, new products and new business initiatives. Freight cost spikes from the Middle East conflict (rerouting around Africa, air freight substitution) are a contributor but not the largest piece.
• Full-year guardrails: SG&A expected at 27.5-28% of revenue, R&D at 8.5-9%, and normal ETR at 24-25%. Amortization is not material and is at normal levels; the freight spike and a few other items are the one-off components within SG&A.
• Inorganic capacity: Approximately US$2.5 billion available without changing credit ratings. India is a priority, but management will not do deals where interest cost exceeds the EBITDA acquired; deals must be better than cost of capital.

Israeli: "We feel, the fact that the branded generics market is now single digit, plus the cost of capital went up over the years, and presently in this situation that if you have a cash transaction, at least, we don't see a reason to buy EBITDA in which only the interest that we will pay to the banks will be more than the EBITDA that we'll get."

Regulatory & Operational Updates

• Two USFDA Form 483s: In May, a routine GMP inspection at two Duvvada, Vizag formulations facilities resulted in a Form 483 with two observations. In June, a GMP inspection at the Srikakulam API facility resulted in a Form 483 with four observations. The company will address and resolve within stipulated timelines.
• CFO transition: Parag Agarwal retires effective August 31, 2024. M. V. Narasimham (MVN), currently Deputy CFO, takes over from August 1, 2024.
• Free cash flow: Lower sequentially due to a fluctuation in factoring; the company rolled back factoring somewhat this quarter depending on interest rates and benefit. Operational cash flow from the business is in line with normal trends.
• ESG recognition: Only Indian pharma company in Time Magazine's 2024 'Global 500 Most Sustainable Companies'; named 'Asia-Pacific Climate Leader' by Financial Times for the second consecutive year, scoring highest among Indian pharma peers.

Guidance & Commitments

Key Metrics